Medicine Overview of Pioglaz Tablet
Uses of Pioglaz Tablet
Pioglaz 15mg Tablet is used in the treatment of type 2 diabetes
It is used in addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
It is used in addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
Side effects of Pioglaz Tablet
Weight gain, Blurred vision, Respiratory tract infection, Numbness, Bone fracture.
How to use Pioglaz Tablet
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. It can be taken with or without food, but it is better to take Pioglaz 15mg Tablet at a fixed time.
How Pioglaz Tablet works
Pioglaz 15mg tablet is an anti-diabetic medication. It works by increasing the body's sensitivity to insulin, a natural substance that helps control blood sugar levels.
In Depth Information on Pioglaz Tablet
Expert advice for Pioglaz Tablet
- Pioglaz helps to control blood sugar level and avoids long-term complications.
- Full effect may be visible after several weeks of starting Pioglaz.
- Weight gain, headache, and swelling due to fluid build-up may occur.
- Notify your doctor if you experience shortness of breath, heart problems, or any abnormal swelling.
- May not be suitable for patients with a history of heart failure or bladder cancer.
- You should continue to exercise regularly, eat a healthy diet, and take your other diabetes medicines along with Pioglaz.
Special precautions for Pioglaz 15mg Tablet
Taking pioglitazone with alcohol may affect blood glucose levels in patients with diabetes.
WEIGH RISKS VS BENEFITS
Pioglaz 15mg Tablet may be unsafe to use during pregnancy.+more
Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor....
Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
Pioglaz 15mg Tablet is probably safe to use during lactation. Limited human data suggests that the drug does not represent a significant risk to the baby.+more
Monitor the breastfed baby’s blood sugar during treatment with Pioglaz 15mg Tablet...
Monitor the breastfed baby’s blood sugar during treatment with Pioglaz 15mg Tablet
Pioglaz 15mg Tablet does not usually affect your ability to drive.
Pioglaz 15mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Pioglaz 15mg Tablet is recommended.+more
Use of Pioglaz 15mg Tablet is not recommended in patients undergoing dialysis....
Use of Pioglaz 15mg Tablet is not recommended in patients undergoing dialysis.
Pioglaz 15mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Pioglaz 15mg Tablet may be needed. Please consult your doctor.+more
Use of Pioglaz 15mg Tablet is not recommended in patients with severe liver disease....
Use of Pioglaz 15mg Tablet is not recommended in patients with severe liver disease.
Severely interacts with other drugs like
Dexadran 4mg Injection, Decamycin 4mg Injection, Manoprolol 40mg Tablet, Walacort 0.5mg Tablet
If you miss a dose of Pioglitazone, skip it and continue with your normal schedule. Do not double the dose.
Frequently asked questions for Pioglaz 15mg Tablet
Frequently asked questions for Pioglitazone
No. Pioglaz is an anti-diabetic medication. Blood thinners are the medicine that prevents the formation of a harmful blood clot. These include medicines like Aspirin, Heparin and Warfarin.
Q. Is Pioglaz a diuretic?
No. Pioglaz is not a diuretic. It is used in the treatment of Diabetes Mellitus. Diuretics are those medicine which increases urination.
Q. Can Pioglaz used in Hepatitis B infection?
Some studies have shown that Pioglaz may be helpful in preventing Hepatitis B Virus-associated Hepatocellular Cancer (Liver Cancer). However, these findings are still very preliminary and clear role has not been established.
Pioglaz has been shown to inhibit Liver Cancer (HCC) recurrence in overweight Hepatitis C Virus-infected diabetic patients. It also improved insulin resistance (a state where the body is resistant to the effects and functions of the insulin hormone) in them.
Q. Can Pioglaz used along with Vitamin D?
Studies indicate that Vitamin-D combined with Pioglaz may be more effective in improving Bone Mineral Density and Bone Metabolism than Vitamin-D or Pioglaz alone in the treatment of Diabetes Mellitus patients with kidney dysfunction (Diabetic Nephropathy).
Q. Can Pioglaz be used along with sitagliptin?
Combination therapy with Sitagliptin and Pioglaz leads to a substantial and sustained improvement in glycemic (blood sugar) control compared to the treatment with Pioglaz alone. This is useful for patients who cannot tolerate Metformin or Sulfonylureas.
Recent evidence suggests that Pioglaz may be beneficial in Alzheimer's disease (AD), decreasing the cognitive decline early in the disease process. However, larger studies are now in progress to establish the same.
Q. Can Pioglaz and repaglinide combined in diabetes treatment?
For patients who previously failed oral antidiabetic therapy, the combination of Repaglinide and Pioglaz have acceptable safety, with greater reductions of glycemic parameters (blood sugar levels) than using either agent alone.
Large population studies indicate that Pioglaz is associated with an increased risk of bladder cancer. The absence of an association of bladder cancer with the other drug of the same class, Rosiglitazone, suggests that the increased risk is drug specific and not a class effect.
Q. Are Pioglaz and rosiglitazone same?
Pioglaz & Rosiglitazone both belong to a class of antidiabetics called Thiazolidinediones. Rosiglitazone has been removed from the market because using this drug was associated with increased risk of cardiovascular events like heart attack and stroke. This is not seen with Pioglaz.
Q. Can Pioglaz be used along with glimepiride in diabetes?
Pioglaz when added to Glimepiride in Patients with Diabetes Mellitus, has been found to significantly reduce plasma lipid levels and significant improvement in blood pressure control related to a reduction in the insulin resistance.
No. Pioglaz is not a steroid. It is an anti-diabetic medication which belongs to the class of thiazolidinediones.
Pioglaz is an anti-diabetes drug used along with a proper diet and exercise program to control high blood sugar in patients with type 2 diabetes. Pioglaz acts as an insulin sensitizer and decreases the extent of insulin resistance in the body too.
Pioglaz cardiovascular safety profile compares favourably with that of Rosiglitazone. Pioglaz has been found to be associated with bladder tumours but causality assessment has not been proved yet.
Pioglaz increases the permeability of fluid in tiny blood vessels called capillaries. This results in easier movement of fluids across the membrane and their consequent accumulation, resulting in oedema (puffiness). Also, Pioglaz causes increased sodium and water reabsorption from the kidney that contributes to the oedema.
The mechanism behind the link between Pioglaz use and bladder cancer is still unknown. Studies have suggested that use of Pioglaz for more than one year results in increased risk of development of tumour of the urinary bladder.
Pioglaz can cause fluid retention and edema. Consequently, there is a lot of fluid in the body (fluid overload). As a result, it may precipitate heart failure (which worsens with fluid overload in those at risk).
Studies in animals have concluded that Pioglaz improves the elasticity of the aortic wall ( the aorta is a large blood vessel that arises from the heart and supplies oxygenated blood to the rest of the body). This may be a mechanism by which it protects against atherosclerosis, but more studies are needed to confirm this.
The addition of Pioglaz reduces daily insulin dosages, but study findings have not been consistent. Improvement of lipid profiles has also been weak with this combination therapy. Long-term studies are needed before any conclusions can be reached. Combination therapy should be primarily used for patients who achieve an insufficient reduction in blood sugar with insulin alone.
Q. Which is not safe in heart failure, Pioglaz or rosiglitazone?
Pioglaz & Rosiglitazone both belong to a class of antidiabetics called Thiazolidinediones. Rosiglitazone has been removed from the market because using this drug was associated with increased risk of cardiovascular events like heart attack and stroke. Pioglaz can cause heart failure too, but the risk is less that that with Rosiglitazone. Both the medicines should be avoided in heart failure.
Fortunately, there are many alternatives to Pioglaz- Metformin, Acarbose, Sitagliptin, Exenatide, Insulin or combination therapies of these medicines can be used.
Findings indicate that Pioglaz treatment is associated with a reduced dementia risk in Diabetes mellitus patients. Prospective studies are needed to evaluate a possible neuroprotective effect in these patients in an ageing population.
Pioglaz may be of use in infertile patients with polycystic ovary syndrome (PCOS) who are resistant to conventional ovulation induction such as by drugs like Clomiphene, Dexamethasone, or Metformin.
The use of Pioglaz for plaque psoriasis treatment is controversial. Some studies revealed no effect of Pioglaz 30 mg daily neither on the clinical response of moderate-to-severe psoriasis whereas others demonstrate that it could be considered as an efficacious and safe agent for the treatment of plaque psoriasis.
In a research study in a small number of autistic children, daily treatment with 30 or 60 mg Pioglaz for 3–4 months induced apparent clinical improvement. Pioglaz should be considered for further testing of therapeutic potential in autistic patients but as of now, autism is not an approved indication for Pioglaz use.
Pioglaz, either alone or as add-on therapy to conventional treatments, could clinically benefit patients of major depression according to a study.
A recent study shows that although Pioglaz causes a significant decrease in blood sugar, HbA1C and lipid levels, it is associated with weight gain, which would limit its utility. It has not been shown to cause weight loss.
Pioglaz has also been used to treat non-alcoholic steatohepatitis (fatty liver), but this use is presently considered experimental.
Pioglaz reduces recurrent stroke and major vascular events in stroke patients with insulin resistance, prediabetes, and diabetes mellitus. However, its use as a preventive therapy requires more research.
One of the following vendor pharmacies will deliver Pioglaz 15mg Tablet: 9T9, KHH, OIP, ENP, PSP, ADT, RKS, MPC, DPP, JMJ, RSA, ATL, JIV, MAK, LHA, GTK, GNC, NDP, HIP, SHM, DYG, MOM, AAY, GPT, FGH, OWP, HEX, USF, BDN, HGI, HBV, SBL, AYU, NVL, SBA, WSI, DFP, BSN, RSS, EQN, ZVP, STA, AGT, PLT, DLP, SAF, LCC, SHP, SAT, OLT, BIO, PNT, MAX, EMB, SSA, GTC, OHM, RPP, SWA, IPL, DEL, RJH, NWP, BTM, SJP, BLP, ATP, RUS, RHW, AAR, PTS, PEN, DDR, MMS